KR20240005856A - 세포 외 트랩 억제 - Google Patents

세포 외 트랩 억제 Download PDF

Info

Publication number
KR20240005856A
KR20240005856A KR1020237041716A KR20237041716A KR20240005856A KR 20240005856 A KR20240005856 A KR 20240005856A KR 1020237041716 A KR1020237041716 A KR 1020237041716A KR 20237041716 A KR20237041716 A KR 20237041716A KR 20240005856 A KR20240005856 A KR 20240005856A
Authority
KR
South Korea
Prior art keywords
seq
antibody
amino acid
acid sequence
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237041716A
Other languages
English (en)
Korean (ko)
Inventor
헬무트 헨드리커스 제랄더스 반 이에스
레나토 제랄더스 실바노 키리비
다프네 몬티잔
에릭 찰스 멜드럼
Original Assignee
씨트릴 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21172160.0A external-priority patent/EP4085973A1/en
Application filed by 씨트릴 비.브이. filed Critical 씨트릴 비.브이.
Publication of KR20240005856A publication Critical patent/KR20240005856A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020237041716A 2021-05-04 2022-05-04 세포 외 트랩 억제 Pending KR20240005856A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21172160.0A EP4085973A1 (en) 2021-05-04 2021-05-04 Inhibition of eosinophil extracellular traps
EP21172160.0 2021-05-04
GB2111541.5 2021-08-11
GB202111541 2021-08-11
PCT/EP2022/061970 WO2022233931A1 (en) 2021-05-04 2022-05-04 Inhibition of eosinophilic traps

Publications (1)

Publication Number Publication Date
KR20240005856A true KR20240005856A (ko) 2024-01-12

Family

ID=81392799

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237041716A Pending KR20240005856A (ko) 2021-05-04 2022-05-04 세포 외 트랩 억제

Country Status (9)

Country Link
US (1) US20250084154A1 (https=)
EP (1) EP4333981A1 (https=)
JP (1) JP2024521638A (https=)
KR (1) KR20240005856A (https=)
AU (1) AU2022270356A1 (https=)
CA (1) CA3215452A1 (https=)
IL (1) IL308223A (https=)
MX (1) MX2023013021A (https=)
WO (1) WO2022233931A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3841120B1 (en) 2018-08-21 2025-09-24 Citryll B.V. Antibodies binding to citrullinated histone 2a and/or 4
EP4442705A1 (en) 2023-04-03 2024-10-09 Citryll B.V. Dosage
GB202318703D0 (en) 2023-12-07 2024-01-24 Citryll B V Diagnostic agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
NO2294086T3 (https=) 2008-06-04 2018-02-10
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
EP2332987A1 (en) 2009-12-10 2011-06-15 ModiQuest B.V. Anti-inflammatory agents directed against citrullinated epitopes
JP7037940B2 (ja) 2014-12-11 2022-03-17 シトリル べー．フェー． 特発性肺線維症の治療方法
EP3841120B1 (en) 2018-08-21 2025-09-24 Citryll B.V. Antibodies binding to citrullinated histone 2a and/or 4

Also Published As

Publication number Publication date
IL308223A (en) 2024-01-01
MX2023013021A (es) 2024-02-12
AU2022270356A1 (en) 2023-09-14
JP2024521638A (ja) 2024-06-04
US20250084154A1 (en) 2025-03-13
CA3215452A1 (en) 2022-11-10
WO2022233931A1 (en) 2022-11-10
EP4333981A1 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
JP7835788B2 (ja) シトルリン化されたヒストン２ａ及び／又は４に結合する抗体
JP6722293B2 (ja) 終末糖化産物（ａｇｅ）に対する抗体を使用して、がんを治療、転移性がん細胞を殺傷、及びがん転移を予防するための方法及び組成物
US20250084154A1 (en) Inhibition of eosinophilic traps
KR20250067121A (ko) Cnx 항원-결합 분자
US20250346656A1 (en) Methods for treating diabetic kidney disease and glomerular disease
US20190002588A1 (en) Anti-myl9 antibody
US12600778B2 (en) Rage antibodies, fragments and uses thereof
US11965038B2 (en) Pharmaceutical composition comprising antibody binding specifically to lysyl-tRNA synthetase N-terminus as effective ingredient for preventing or treating immune cell migration-related disease
CN117396221A (zh) 嗜酸性粒细胞陷阱的抑制
EP4085973A1 (en) Inhibition of eosinophil extracellular traps
EA052640B1 (ru) Ингибирование внеклеточных ловушек
US12161889B2 (en) Blood brain barrier (BBB)-selective antibodies and methods of use thereof to target agents to the BBB
EP4442705A1 (en) Dosage
JP2026513830A (ja) 用量
WO2025120152A1 (en) Diagnostic agent
HK40128527A (en) Antibodies binding to citrullinated histone 2a and/or 4
JP2022518796A (ja) 肺、腎臓、または肝臓の線維症疾患の処置に使用するためのｐｓｍｐアンタゴニスト

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231201

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250425

Comment text: Request for Examination of Application